Advertisement
Canada markets open in 25 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    84.27
    +0.70 (+0.84%)
     

  • Bitcoin CAD

    87,581.46
    +1,077.43 (+1.25%)
     

  • CMC Crypto 200

    1,388.93
    -7.61 (-0.54%)
     

  • GOLD FUTURES

    2,353.40
    +10.90 (+0.47%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.6800
    -0.0260 (-0.55%)
     

  • NASDAQ futures

    17,700.50
    +133.00 (+0.76%)
     

  • VOLATILITY

    15.50
    +0.13 (+0.84%)
     

  • FTSE

    8,119.30
    +40.44 (+0.50%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6831
    +0.0010 (+0.15%)
     
MARKETS LIVE BLOG:

STOCK FUTURES JUMP, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting

News Direct
·1 min read

New York --News Direct-- Context Therapeutics

Context Therapeutics CEO Marty Lehr joins Proactive's Natalie Stoberman to discuss CTIM-76 preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Lehr noted the latest CTIM-76 bispecific antibody data and developments were shared with investors and colleagues as Context prepares for an Investigational New Drug application filing in early 2024.

CTIM-76 is a Claudin 6 (CLDN6) X CD3 bispecific antibody currently in preclinical development that is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CLDN6 is expressed in multiple solid tumors, including ovarian, lung, and testicular cancers.

ADVERTISEMENT

The R&D webinar presentation can be found here: https://ir.contexttherapeutics.com/static-files/9377e4ba-bce3-4daa-a4f5-708b6a7c61dc

Contact Details

Proactive Investors USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/context-therapeutics-ctim-76-bispecific-antibody-preclinical-data-presented-at-aacr-annual-meeting-706192599